Co-Host: Brian M. Shuch, MD

At the conclusion of these activities, participants will be able to:

1. Describe a patient-specific treatment plan that optimizes the use of targeted and immunological agents for the treatment of kidney cancer.

2. Explain best practices in RCC patient selection for various treatment options

CME Available: https://auau.auanet.org/node/26099

This educational series is supported by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Merck

Pfizer, Inc.

Sanofi Genzyme

UroGen Pharma